% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Piroth:20427,
      author       = {Piroth, M.D. and Pinkawa, M. and Holy, R. and Klotz, J. and
                      Schaar, S. and Stoffels, G. and Galldiks, N. and Coenen,
                      H.H. and Kaiser, H.J. and Langen, K.J. and Eble, M.J.:},
      title        = {{I}ntegrated boost {IMRT} with {FET}-{PET}-adapted local
                      dose escalation in glioblastomas: {R}esults of a prospective
                      phase {II} study},
      journal      = {Strahlentherapie und Onkologie},
      volume       = {188},
      issn         = {0179-7158},
      address      = {Berlin},
      publisher    = {Springer Medizin},
      reportid     = {PreJuSER-20427},
      pages        = {334 - 339},
      year         = {2012},
      note         = {Record converted from VDB: 12.11.2012},
      abstract     = {Dose escalations above 60 Gy based on MRI have not led to
                      prognostic benefits in glioblastoma patients yet. With
                      positron emission tomography (PET) using
                      [(18)F]fluorethyl-L-tyrosine (FET), tumor coverage can be
                      optimized with the option of regional dose escalation in the
                      area of viable tumor tissue.In a prospective phase II study
                      (January 2008 to December 2009), 22 patients (median age
                      55 years) received radiochemotherapy after surgery. The
                      radiotherapy was performed as an MRI and FET-PET-based
                      integrated-boost intensity-modulated radiotherapy (IMRT).
                      The prescribed dose was 72 and 60 Gy (single dose 2.4 and
                      2.0 Gy, respectively) for the FET-PET- and MR-based
                      PTV-FET((72 Gy)) and PTV-MR((60 Gy)). FET-PET and MRI were
                      performed routinely for follow-up. Quality of life and
                      cognitive aspects were recorded by the EORTC-QLQ-C30/QLQ
                      Brain20 and Mini-Mental Status Examination (MMSE), while the
                      therapy-related toxicity was recorded using the CTC3.0 and
                      RTOG scores.Median overall survival (OS) and disease-free
                      survival (DFS) were 14.8 and 7.8 months, respectively. All
                      local relapses were detected at least partly within the
                      $95\%$ dose volume of PTV-MR((60 Gy)). No relevant
                      radiotherapy-related side effects were observed (excepted
                      alopecia). In 2 patients, a pseudoprogression was observed
                      in the MRI. Tumor progression could be excluded by FET-PET
                      and was confirmed in further MRI and FET-PET imaging. No
                      significant changes were observed in MMSE scores and in the
                      EORTC QLQ-C30/QLQ-Brain20 questionnaires.Our dose escalation
                      concept with a total dose of 72 Gy, based on FET-PET, did
                      not lead to a survival benefit. Acute and late toxicity were
                      not increased, compared with historical controls and
                      published dose-escalation studies.},
      keywords     = {Adult / Aged / Brain: radiation effects /
                      Chemoradiotherapy, Adjuvant / Combined Modality Therapy /
                      Disease-Free Survival / Dose Fractionation / Female /
                      Follow-Up Studies / Glioblastoma: drug therapy /
                      Glioblastoma: mortality / Glioblastoma: pathology /
                      Glioblastoma: radiotherapy / Glioblastoma: surgery / Humans
                      / Magnetic Resonance Imaging / Male / Mental Status Schedule
                      / Middle Aged / Positron-Emission Tomography: methods /
                      Prospective Studies / Quality of Life / Radiation Injuries:
                      etiology / Radiotherapy Planning, Computer-Assisted: methods
                      / Radiotherapy, Intensity-Modulated: methods /
                      Supratentorial Neoplasms: drug therapy / Supratentorial
                      Neoplasms: mortality / Supratentorial Neoplasms: pathology /
                      Supratentorial Neoplasms: radiotherapy / Supratentorial
                      Neoplasms: surgery / Tyrosine: analogs $\&$ derivatives /
                      Tyrosine: therapeutic use /
                      O-(2-((18)F)fluoroethyl)-L-tyrosine (NLM Chemicals) /
                      Tyrosine (NLM Chemicals) / J (WoSType)},
      cin          = {INM-4 / INM-5 / INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-4-20090406 / I:(DE-Juel1)INM-5-20090406 /
                      I:(DE-Juel1)INM-3-20090406},
      pnm          = {Funktion und Dysfunktion des Nervensystems (FUEK409) /
                      89572 - (Dys-)function and Plasticity (POF2-89572)},
      pid          = {G:(DE-Juel1)FUEK409 / G:(DE-HGF)POF2-89572},
      shelfmark    = {Oncology / Radiology, Nuclear Medicine $\&$ Medical
                      Imaging},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:22349712},
      UT           = {WOS:000301776900005},
      doi          = {10.1007/s00066-011-0060-5},
      url          = {https://juser.fz-juelich.de/record/20427},
}